Ashok Venkitaraman
Founder at Sentinel Oncology Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stuart Travers | M | - |
Sentinel Oncology Ltd.
 Sentinel Oncology Ltd. BiotechnologyHealth Technology Sentinel Oncology Ltd. operates as a molecule drug discovery company. The firm develops and commercializes new therapeutics to treat cancer where there is an unmet medical need. The company was founded by Stuart Travers, Robert G. Boyle, Ashok Venkitaraman and Gavin Simpson in 2005 and is headquartered in Cambridge, the United Kingdom. | 19 years |
| Robert G. Boyle | M | - |
Sentinel Oncology Ltd.
Sentinel Oncology Ltd. BiotechnologyHealth Technology Sentinel Oncology Ltd. operates as a molecule drug discovery company. The firm develops and commercializes new therapeutics to treat cancer where there is an unmet medical need. The company was founded by Stuart Travers, Robert G. Boyle, Ashok Venkitaraman and Gavin Simpson in 2005 and is headquartered in Cambridge, the United Kingdom. | 19 years |
| Neil Torbett | M | - |
PhoreMost Ltd.
 PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 7 years |
| Christopher Torrance | M | - |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 10 years |
| Ronne Yeo | M | - |
Esco Ventures Pte Ltd.
 Esco Ventures Pte Ltd. Investment ManagersFinance Esco Ventures Pte Ltd (Esco Ventures) is a venture capital firm founded in 2014 by Mr. Dr Nir Arbel and XiangQian (XQ) Lin. The firm is headquartered in Singapore. | - |
| Len Blavatnik | M | 66 |
University of Cambridge
| - |
| Jonathan Milner | M | 59 |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 9 years |
| Xiang Qian Lin | M | 40 |
Esco Ventures Pte Ltd.
Esco Ventures Pte Ltd. Investment ManagersFinance Esco Ventures Pte Ltd (Esco Ventures) is a venture capital firm founded in 2014 by Mr. Dr Nir Arbel and XiangQian (XQ) Lin. The firm is headquartered in Singapore. | 10 years |
| Bengt Westermark | M | 79 |
European Molecular Biology Organization
| - |
| Gavin Simpson | M | - |
Sentinel Oncology Ltd.
Sentinel Oncology Ltd. BiotechnologyHealth Technology Sentinel Oncology Ltd. operates as a molecule drug discovery company. The firm develops and commercializes new therapeutics to treat cancer where there is an unmet medical need. The company was founded by Stuart Travers, Robert G. Boyle, Ashok Venkitaraman and Gavin Simpson in 2005 and is headquartered in Cambridge, the United Kingdom. | 19 years |
| Charli Batley | M | - |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 9 years |
| David Glover | M | - |
European Molecular Biology Organization
University of Cambridge
| - |
| Grahame McKenzie | M | - |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 10 years |
| Fiona Gilbert | F | - |
University of Cambridge
| - |
| Bradley Fried | M | 59 |
University of Cambridge
| - |
| Priya Shah | F | - |
University of Cambridge
| 1 years |
| Dame Alison F. Richard | M | - |
University of Cambridge
| - |
| Peter Nolan | M | 75 |
University of Cambridge
| 45 years |
| Zeeshan Ali | M | - |
University of Cambridge
| - |
| Bill Milne | M | - |
University of Cambridge
| - |
| Frank Kelly | M | - |
University of Cambridge
| - |
| José Lopez | M | 72 |
University of Cambridge
| - |
| Keith Glover | M | - |
University of Cambridge
| 10 years |
| Nalin Satykam Kohli | M | - |
University of Cambridge
| - |
| Douglas Christopher Patrick McDougall | M | 80 |
University of Cambridge
| - |
| Andrew Woods | M | - |
University of Cambridge
| - |
| Luke O'Neill | M | 60 |
European Molecular Biology Organization
| 19 years |
| Peter Williamson | M | 67 |
University of Cambridge
| - |
| Sanaya Morawala-Patell | F | - |
University of Cambridge
| - |
| Clare Woodcraft-Scott | F | - |
University of Cambridge
| 4 years |
| Bruce Beckles | M | - |
University of Cambridge
| - |
| David Hampton | M | - |
University of Cambridge
| - |
| Raymond Kaempfer | M | - |
European Molecular Biology Organization
| - |
| Martin Faulkes | M | 80 |
University of Cambridge
| - |
| Haider Zameer Choudrey | M | 37 |
University of Cambridge
| - |
| Alan Ashworth | M | 63 |
European Molecular Biology Organization
| - |
| Ian Hugh White | M | - |
University of Cambridge
| - |
| Antonio Lanzavecchia | M | 73 |
European Molecular Biology Organization
| - |
| Fulvio Mavilio | M | - |
European Molecular Biology Organization
| - |
| Brian A. Ference | M | - |
University of Cambridge
| - |
| William McDonnell | M | - |
University of Cambridge
| - |
| Dirk Heinz | M | - |
European Molecular Biology Organization
| 15 years |
| Chris Rider | M | - |
University of Cambridge
| - |
| Karen Vousden | M | 66 |
European Molecular Biology Organization
| - |
| Roger A. Pedersen | M | - |
University of Cambridge
| - |
| Shankar Balasubramanian | M | - |
University of Cambridge
| - |
| Paul Schulze Lefert | M | - |
European Molecular Biology Organization
| - |
| Arokia Nathan | M | - |
University of Cambridge
| - |
| Onora Sylvia O'Neill | F | - |
University of Cambridge
| - |
| Patrick Maxwell | M | 62 |
University of Cambridge
| - |
| Carl-Hendrik Heldin | M | 72 |
European Molecular Biology Organization
| 8 years |
| James Appleby | M | - |
University of Cambridge
| 6 years |
| Arjun K. Mathrani | M | 79 |
University of Cambridge
| - |
| Alan H. Windle | M | - |
University of Cambridge
| - |
| John Leonard Eatwell | M | 79 |
University of Cambridge
| 54 years |
| Edward N. Brody | M | - |
European Molecular Biology Organization
| - |
| David Walker | M | 84 |
University of Cambridge
| - |
| Erkki Ruoslahti | M | 84 |
European Molecular Biology Organization
| - |
| John Charles Shakeshaft | M | 70 |
University of Cambridge
| - |
| Andrew Morgan | M | 68 |
University of Cambridge
| - |
| Bruce Ponder | M | - |
University of Cambridge
| - |
| Christopher Robin Lowe | M | 79 |
University of Cambridge
| - |
| J. Kenneth Charles Knowles | M | 77 |
European Molecular Biology Organization
| - |
| Elizabeth Peace | F | 72 |
University of Cambridge
| - |
| Stephen Jackson | M | 62 |
University of Cambridge
| - |
| Stephen Evans-Freke | M | 72 |
University of Cambridge
| - |
| Henning Sirringhaus | M | 59 |
University of Cambridge
| - |
| Joseph P. Schlessinger | M | 79 |
European Molecular Biology Organization
| - |
| Hans Lennart Rudolf Wigzell | M | 86 |
European Molecular Biology Organization
| - |
| Ian J. Lewis | M | 63 |
University of Cambridge
| - |
| Khalid Yosif Abdulla-Janahi | M | - |
University of Cambridge
| - |
| Rona Alison Fairhead | F | 63 |
University of Cambridge
| - |
| Carol J. Hochman | F | 73 |
University of Cambridge
| - |
| Charles Gordon Smith | M | - |
University of Cambridge
| - |
| Andrew Hopper | M | 71 |
University of Cambridge
| - |
| Matthew Bullock | M | 75 |
University of Cambridge
| - |
| Richard Friend | M | 71 |
University of Cambridge
| - |
| David Cebon | M | - |
University of Cambridge
| - |
| Stefanos Capsaskis | M | 66 |
University of Cambridge
| 7 years |
| Christopher Town | M | - |
University of Cambridge
| - |
| Andrew D. Hall | M | - |
University of Cambridge
| - |
| Emma Rothschild | F | 76 |
University of Cambridge
| - |
| Laurence Harris Pearl | M | - |
European Molecular Biology Organization
| - |
| Derek Robert McAuley | M | - |
University of Cambridge
| - |
| Gus MacIver | M | - |
University of Cambridge
| - |
| Peter Ratcliffe | M | 69 |
European Molecular Biology Organization
| - |
| John Lee | M | 74 |
University of Cambridge
| - |
| Alan Bradley | M | 64 |
University of Cambridge
| - |
| Florin Udrea | M | - |
University of Cambridge
| - |
| Anthony David Stalbow | M | 85 |
University of Cambridge
| - |
| Gehan Anil Joseph Amaratunga | M | - |
University of Cambridge
| 28 years |
| Richard V. Penty | M | - |
University of Cambridge
| 23 years |
| Ruth Arnon | M | 91 |
European Molecular Biology Organization
| - |
| Samir I. Toubassy | M | - |
University of Cambridge
| - |
| Nigel Slater | M | 70 |
University of Cambridge
| - |
| Martin Rees | M | - |
University of Cambridge
| - |
| James Augustus Henry Murray | M | 63 |
University of Cambridge
| - |
| Robert Kamen | M | 79 |
European Molecular Biology Organization
| 48 years |
| Daniel L. Farkas | M | 70 |
European Molecular Biology Organization
| - |
| Gloria Ho | F | - |
Esco Ventures Pte Ltd.
Esco Ventures Pte Ltd. Investment ManagersFinance Esco Ventures Pte Ltd (Esco Ventures) is a venture capital firm founded in 2014 by Mr. Dr Nir Arbel and XiangQian (XQ) Lin. The firm is headquartered in Singapore. | 4 years |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 77 | 77.00% |
| Germany | 21 | 21.00% |
| Singapore | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ashok Venkitaraman
- Personal Network